Notice of Intent To Grant an Exclusive License, 42414-42415 [05-14542]

Download as PDF 42414 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices contentions and the legal and factual issues raised. b. Withdrawal of Services by a Representative: When the appellant’s representative withdraws from a case, both the appellant and the BVA must be informed so that the appellant’s rights may be adequately protected and so that the BVA may meet its statutory obligations to provide notice to the current representative. c. Filing of Representative’s Fee Agreements and Motions for Review of Such Agreements: Agreements for fees charged by individuals or organizations for representing claimants and appellants before VA are filed with, and reviewed by, the Board of Veterans’ Appeals. The information is used to determine whether such fees are excessive or unreasonable. d. Motion for Review of Representative’s Charges for Expenses: Expense reimbursements claimed by individuals and organizations for representing claimants and appellants before VA have been monitored for fairness for many years. The information is used to review changes by claimants’ representatives for expenses to afford protection to such claimants from overreaching by unscrupulous representatives and is useful in monitoring fees charged by representatives and to ensure that fee limitations are not avoided by mischaracterizing fees as expenses. e. Request for Changes in Hearing Date: VA provides hearings to appellants and their representatives, as required by basic Constitutional dueprocess and by Title 38 U.S.C. 7107(b). From time to time, hearing dates and/or times are changed, hearing requests withdrawn and new hearings requested after failure to appear at a scheduled hearing. The information is used to comply with the appellants’ or their representatives’ requests. f. Motion for Reconsideration: Decisions by BVA are final unless the Chairman orders reconsideration of the decision either on the Chairman’s initiative, or upon motion of a claimant. The Board Chairman, or his designee, uses the information provided in deciding whether reconsideration of a Board decision should be granted. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The Federal Register Notice with a 60-day comment period soliciting comments on this collection of information was published on March 18, 2005 at pages 13235–13236. VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 Affected Public: Individuals or households, Business or other for profit, and Not for profit institutions. Estimated Total Annual Burden: a. Appeal to Board of Veterans’ Appeals, VA Form 9—49,700 hours. b. Withdrawal of Services by a Representative—183 hours. c. Filing of Representative’s Fee Agreements and Motions for Review of Such Agreements—207 hours. d. Motion for Review of Representative’s Charges for Expenses— 4 hours. e. Request for Changes in Hearing Date—946 hours. f. Motion for Reconsideration—859 hours. Estimated Average Burden Per Respondent: a. Appeal to Board of Veterans’ Appeals, VA Form 9—1 hour. b. Withdrawal of Services by a Representative—20 minutes. c. Filing of Representative’s Fee Agreements and Motions for Review of Such Agreements—10 minutes (basic filing), 1 hour (contract modifications),—2 hours (filing motion or response). d. Motion for Review of Representative’s Charges for Expenses— 4 hours (2 hours for motion and 2 hours for response to motion). e. Request for Changes in Hearing Date—15 minutes (hearing date change), 15 minutes (request to withdraw a hearing),—1 hour (requests change a motion). f. Motion for Reconsideration—1 hour. Frequency of Response: On occasion. Estimated Total Number of Respondents: a. Appeal to Board of Veterans’ Appeals, VA Form 9—49,700. b. Withdrawal of Services by a Representative—550. c. Filing of Representative’s Fee Agreements and Motions for Review of Such Agreements—937. d. Motion for Review of Representative’s Charges for Expenses— 2. e. Request for Changes in Hearing Date—1,716. f. Motion for Reconsideration—859. Dated: July 13, 2005. By direction of the Secretary. Denise McLamb, Program Analyst, Records Management Service. [FR Doc. 05–14543 Filed 7–21–05; 8:45 am] BILLING CODE 8320–01–P PO 00000 Frm 00116 Fmt 4703 Sfmt 4703 DEPARTMENT OF VETERANS AFFAIRS Notice of Intent To Grant an Exclusive License Department of Veterans Affairs, Office of Research and Development. ACTION: Notice of intent. AGENCY: SUMMARY: Notice is hereby given that the Department of Veterans Affairs, Office of Research and Development, intends to grant to CellCyte Genetics, Inc., PO Box 493, Kirkland, WA 98083 USA an exclusive license to practice the following patent applications: U.S. Provisional Patent Application Serial No. 60/364,498 filed March 15, 2002, entitled ‘‘Methods and Compositions for Directing Cells to Target Organs’’; U.S. Patent Application Serial No. 10/ 388,964 filed March 14, 2003, entitled ‘‘Methods and Compositions for Directing Cells to Target Organs’’; International Patent Application Serial No. PCT/US03/07834 filed March 13, 2003, entitled ‘‘Methods and Compositions for Directing Cells to Target Organs’’; International Patent Application Serial No. PCT/US03/07934 filed March 13, 2003, entitled ‘‘Methods and Compositions Using Cellular Asialodeterminants and Glycoconjugates for Targeting Cells to Tissues and Organs’’; International Patent Application Serial No. PCT/ US03/32602 filed October 10, 2003 entitled ‘‘Detection/Localization and Staging of Tumors Using Labeled Activated Lymphocytes Directed to a Tumor Specific Epitope’’ and International Patent Application Serial No. PCT/US03/07836 filed March 14, 2003, entitled ‘‘Methods and Compositions for Directing Cells to Target Organs’’. DATES: Comments must be received within fifteen (15) days from the date of this published Notice. ADDRESSES: Send comments to Saleem J. Sheredos, Acting Director of Technology Transfer, Department of Veterans Affairs; Office of Research and Development, Attn: 12TT; 103 South Gay Street, Baltimore, MD 21202. Telephone: (410) 962–1800 ext 267; Facsimile: (410) 962–2141; e-mail: saleem@vard.org. FOR FURTHER INFORMATION CONTACT: Copies of the published patent applications may be obtained from the U.S. Patent and Trademark Office at http://www.uspto.gov. SUPPLEMENTARY INFORMATION: It is in the public interest to so license these inventions as CellCyte, Inc., submitted a complete and sufficient application for E:\FR\FM\22JYN1.SGM 22JYN1 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Approved: July 13, 2005. Gordon H. Mansfield, Deputy Secretary, Department of Veterans Affairs. [FR Doc. 05–14542 Filed 7–21–05; 8:45 am] BILLING CODE 8320–01–P DEPARTMENT OF VETERANS AFFAIRS Notice of Intent To Grant an Exclusive License Department of Veterans Affairs, Office of Research and Development. ACTION: Notice of intent. AGENCY: SUMMARY: Notice is hereby given that the Department of Veterans Affairs, Office of Research and Development, intends to grant Global Therapy Monitoring LLC, 6931 Arlington Road, Bethesda, MD 20814 USA an exclusive license to practice the following patent applications: U.S. Provisional Patent Application Serial No. 60/547,052 filed February 25, 2004, entitled ‘‘Methods VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 for Diagnosing and Treating Bladder Cancer’’; U.S. Provisional Patent Application Serial No. 60/532,889 filed December 30, 2003, entitled ‘‘Macrophage Migration Inhibitory Factor (MIF) as a Marker for Urological Inflammatory Disease’’; U.S. Patent Application Serial No. 10/644,797 filed on August 21, 2003, and International Patent Application Serial No. PCT/ US04/05288 filed on February 24, 2004, entitled ‘‘Serum Macrophage Migration Inhibitory Factor (MIF) as a Marker for Prostate Cancer.’’ DATES: Comments must be received within fifteen (15) days from the date of this published Notice. ADDRESSES: Send comments to Saleem J. Sheredos, Acting Director of Technology Transfer, Department of Veterans Affairs; Office of Research and Development, Attn: 12TT; 103 South Gay Street, Baltimore, MD 21202. Telephone: (410) 962–1800 ext 267; Facsimile: (410) 962–2141; e-mail: saleem@vard.org. FOR FURTHER INFORMATION CONTACT: Copies of the published patent applications may be obtained from the U.S. Patent and Trademark Office at http://www.uspto.gov. SUPPLEMENTARY INFORMATION: It is in the public interest to so license these inventions as Global Therapy Monitoring LLC submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, PO 00000 Frm 00117 Fmt 4703 Sfmt 4703 42415 within fifteen (15) days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Approved: July 13, 2005. Gordon H. Mansfield, Deputy Secretary of Veterans Affairs. [FR Doc. 05–14541 Filed 7–21–05; 8:45 am] BILLING CODE 8320–01–P DEPARTMENT OF VETERANS AFFAIRS VA Fleet Alternative Fuel Vehicle (AFV) Program Report Department of Veterans Affairs. Notice. AGENCY: ACTION: SUMMARY: In accordance with the Energy Policy Act of 1992 (EPAct) (42 U.S.C. 13211–13219) as amended by the Energy Conservation Reauthorization Act of 1998 (Pub. L. 105–388), the Department of Veterans Affairs’ annual alternative fuel reports are available on the following Department of Veterans Affairs Web site: http://www.va.gov/afv. FOR FURTHER INFORMATION CONTACT: Elaine Jackson, (202) 273–5859. Approved: July 13, 2005. Gordon H. Mansfield, Deputy Secretary of Veterans Affairs. [FR Doc. 05–14540 Filed 7–21–05; 8:45 am] BILLING CODE 8320–01–P E:\FR\FM\22JYN1.SGM 22JYN1

Agencies

[Federal Register Volume 70, Number 140 (Friday, July 22, 2005)]
[Notices]
[Pages 42414-42415]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14542]


-----------------------------------------------------------------------

DEPARTMENT OF VETERANS AFFAIRS


Notice of Intent To Grant an Exclusive License

AGENCY: Department of Veterans Affairs, Office of Research and 
Development.

ACTION: Notice of intent.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Department of Veterans 
Affairs, Office of Research and Development, intends to grant to 
CellCyte Genetics, Inc., PO Box 493, Kirkland, WA 98083 USA an 
exclusive license to practice the following patent applications: U.S. 
Provisional Patent Application Serial No. 60/364,498 filed March 15, 
2002, entitled ``Methods and Compositions for Directing Cells to Target 
Organs''; U.S. Patent Application Serial No. 10/388,964 filed March 14, 
2003, entitled ``Methods and Compositions for Directing Cells to Target 
Organs''; International Patent Application Serial No. PCT/US03/07834 
filed March 13, 2003, entitled ``Methods and Compositions for Directing 
Cells to Target Organs''; International Patent Application Serial No. 
PCT/US03/07934 filed March 13, 2003, entitled ``Methods and 
Compositions Using Cellular Asialodeterminants and Glycoconjugates for 
Targeting Cells to Tissues and Organs''; International Patent 
Application Serial No. PCT/US03/32602 filed October 10, 2003 entitled 
``Detection/Localization and Staging of Tumors Using Labeled Activated 
Lymphocytes Directed to a Tumor Specific Epitope'' and International 
Patent Application Serial No. PCT/US03/07836 filed March 14, 2003, 
entitled ``Methods and Compositions for Directing Cells to Target 
Organs''.

DATES: Comments must be received within fifteen (15) days from the date 
of this published Notice.

ADDRESSES: Send comments to Saleem J. Sheredos, Acting Director of 
Technology Transfer, Department of Veterans Affairs; Office of Research 
and Development, Attn: 12TT; 103 South Gay Street, Baltimore, MD 21202. 
Telephone: (410) 962-1800 ext 267; Facsimile: (410) 962-2141; e-mail: 
saleem@vard.org.

FOR FURTHER INFORMATION CONTACT: Copies of the published patent 
applications may be obtained from the U.S. Patent and Trademark Office 
at http://www.uspto.gov.

SUPPLEMENTARY INFORMATION: It is in the public interest to so license 
these inventions as CellCyte, Inc., submitted a complete and sufficient 
application for

[[Page 42415]]

a license. The prospective exclusive license will be royalty-bearing 
and will comply with the terms and conditions of 35 U.S.C. 209 and 37 
CFR 404.7. The prospective exclusive license may be granted unless, 
within fifteen (15) days from the date of this published Notice, the 
Department of Veterans Affairs Office of Research and Development 
receives written evidence and argument which establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.

    Approved: July 13, 2005.
Gordon H. Mansfield,
Deputy Secretary, Department of Veterans Affairs.
[FR Doc. 05-14542 Filed 7-21-05; 8:45 am]
BILLING CODE 8320-01-P